Amendments to the Specification

On page 1, after the title, please insert the following paragraph and heading:

PRIORITY CLAIM

This is the U.S. National Stage of International Application No. PCT/GB2004/003899, filed September 13, 2004 (published in English under PCT Article 21(2)), which in turn claims the benefit of Great Britain Application No. 0328106.0, filed December 4, 2003, Great Britain Application No. 0404242.0, filed February 26, 2004, and U.S. Provisional Application No. 60/554,852, filed March 19, 2004.

Please replace the paragraphs beginning on page 24, line 19, with the following re-written paragraphs:

--Figure 17a is the ASPP1 nucleic acid sequence (SEQ ID NO: 1); Figure 17b is the ASPP2 nucleic acid sequence (SEQ ID NO: 2); Figure 17c is the ASPP1 protein sequence (SEQ ID NO: 3) ; Figure 17d is the ASPP2 protein sequence (SEQ ID NO: 4);

Figure 18a is the H-Ras wild-type nucleic acid sequence (SEQ ID NO: 5); Figure 18b is the H-Ras protein sequence (SEQ ID NO: 6); Figure 18c is the H-Ras oncogenic nucleic acid sequence (SEQ ID NO: 7); Figure 18d is the H-Ras oncogenic protein sequence (SEQ ID NO: 8); Figure 18e is the K Ras wild-type nucleic acid sequence (SEQ ID NO: 9); Figure 18f is the wild –type K-Ras protein sequence (SEQ ID NO: 10); Figure 18g is the K-Ras oncogenic nucleic acid sequence (SEQ ID NO: 11); and Figure 18h is the K-Ras oncogenic protein sequence (SEQ ID NO: 12);

Figure 19a is the MAPK nucleic acid sequence (SEQ ID NO: 13); Figure 19b is the MAPK protein sequence (SEQ ID NO: 14);

Figure 20a is the PKA nucleic acid sequence (SEQ ID NO: 15); Figure 20b is the PKA protein sequence (SEQ ID NO: 16);

Figure 21a is the phosphatase 1 nucleic acid sequence (SEQ ID NO: 17); Figure 21b is the phosphatase 1 protein sequence (SEQ ID NO: 18); and--

Please replace the paragraph beginning on page 29, line 29, with the following re-written paragraph:

--The mammalian expression vector pSUPER was used for expression of RNAi. In the case of K-Ras RNAi the gene-specific insert specifies a 19-nucleotide sequence corresponding to nucleotides 25-43 downstream of the transcription start site (gttggagctggtggcgtag; SEQ ID NO: 19) of K-Ras, which is separated by a 9-nucleotide noncomplementary spacer (ttcaagaga; SEQ ID NO: 20) from the reverse complement of the same 19- nucleotide sequence. This vector was referred to as K-Ras RNAi. The H-Ras RNAi construct was cloned into the same pSUPER vector with a 20-nucleotide insert corresponding to the nucleotides 299-316 downstream of the transcription start site (tcaaacgggtgaaggactc; SEQ ID NO: 21). These sequences were inserted into the pSUPER.2 backbone after digestion with BglII and HindIII and transformed into TOP10 One ShotTM supercompetent cells (Invitrogen) according to the manufacturer's instructions. Upon ligation, the BglII site is destroyed, allowing for selection of positive clones.--

Please replace the paragraph beginning on page 35, line 20, with the following re-written paragraph:

--The purified C-terminus of ASPP2 was used as a substrate to screen for kinases in an in vitro assay. An array of kinases were added to the purified C-terminus of ASPP2 and the phosphorylation status of the protein was analysed using P32 as a phosphorylation marker. MAPK1, PKA, p38SAPK and p90rsk were all found to be able to phosphorylate ASPP2 (figure 8A). A larger scale in vitro phosphorylation assay was then performed, using the four enzymes that had screened positive in the first round (figure 8B-C). The phosphorylated fragment of ASPP2 was run on a gel, exposed, extracted from the gel and trypsinized. The trypsinized protein was then put through a High Performance Liquid Chromatography (HPLC) with an acetonitrile gradient, the radioactive peptides were then collected and analyzed by mass spectrometry (figure 8D). For the MAPK-phosphorylated ASPP2 C-terminus, there were two phosphorylation sites.

The first one corresponded to the linker region between the GST and the protein. The second phosphorylated site corresponded to a region of the protein that contains a MAPK-consensus sequence phosphorylation site; PAPSPGL (SEQ ID NO: 22).--

Please insert the Abstract, submitted herein on a separate page, as page 56 at the end of the application.

Please replace the sequence listing with the enclosed sequence listing (33 pages submitted on CD-ROM).